Blade Therapeutics to Present at the Stifel 2019 Healthcare Conference
Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 1:50 p.m. Eastern Time.
About Blade Therapeutics
Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade's lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases. BLD-2660 recently completed a Phase I, healthy volunteer, dose escalation study in Australia. The Company plans to submit a CTN application to initiate a Phase II trial in patients with idiopathic pulmonary fibrosis in early 2020. Blade's second candidate, BLD-0409, is a Phase I ready autotaxin inhibitor for the treatment of multiple fibrotic diseases. The Company plans to initiate a Phase 1 study for BLD-0409 in 1Q 2020.
Blade has assembled a critical mass of anti-fibrotic drug development expertise within its top-tier leadership team and a world-class network of advisors. Lead investors in Blade include MPM Capital, Deerfield, Pfizer Ventures, One Ventures, Osage Partners, Bristol-Myers Squibb and Novartis Institute of Biomedical Research. Please visit http://www.blademed.com/ for more information.
Ferrilli, a leading provider of technology solutions for higher education institutions, proudly announces its recognition as the Ellucian Implementation Partner of the Year for 2023. This esteemed award marks the second consecutive year that Ferrilli...
A modified, upgraded, and perfectly preserved 2006 Pontiac GTO sponsored by CRC Industries will be auctioned May 15, 2024 with all proceeds going to TechForce Foundation, a nonprofit organization that funds education for and champions young people...
CareHive Health, a pioneer in data-driven, digital-first, white glove navigation solutions, proudly announces the appointment of Julianne Bride, MBA, as CareHive's Vice President of Strategic Partnerships and Client Success.
Julianne Bride's...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScreen® 2.0, a comprehensive suite of assays that predict and evaluate potential risks of...
Arthritis is a crippling disease, affecting approximately one in four adults. It wreaks havoc on our joints by breaking down cartilage, the cushioning between bones. Once that cartilage deteriorates, there's no way to replace it. However, all this...
Communication Technology Services (CTS), an in-building and campus connectivity solution provider, is proud to announce the opening of its new office in Carrollton, Texas. This expansion marks an important milestone for the company as it continues to...
